CAL
CRSP icon

Capital Analysts LLC’s CRISPR Therapeutics CRSP Stock Holding History

Capital Analysts LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Hold
49
– – ﹤0.01% 1435
2026
Q1 		$2K Hold
49
– – ﹤0.01% 1449
2025
Q4 		$3K Hold
49
– – ﹤0.01% 1381
2025
Q3 		$3K Hold
49
– – ﹤0.01% 1346
2025
Q2 		$2K Hold
49
– – ﹤0.01% 1316
2025
Q1 		$2K Hold
49
– – ﹤0.01% 1303
2024
Q4 		$2K Hold
49
– – ﹤0.01% 1217
2024
Q3 		$2K Hold
49
– – ﹤0.01% 1208
2024
Q2 		$3K Hold
49
– – ﹤0.01% 1078
2024
Q1 		$3K Buy
+49
New +$3.51K ﹤0.01% 1016

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Analysts LLC's CRSP Position: Q2 2026 in Review

Capital Analysts LLC held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 49 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1435.

Capital Analysts LLC first reported a position in CRSP in Q1 2024 and has held it in 10 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital Analysts LLC held 49 shares of CRISPR Therapeutics worth $3K as of Q2 2026.
  • Capital Analysts LLC left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1435 holding.
  • Capital Analysts LLC first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.